EP
BMRN icon

Edgestream Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Edgestream Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.77M Buy
100,897
+66,842
+196% +$3.66M 0.17% 202
2026
Q1 		$1.92M Sell
34,055
-92,296
-73% -$5.38M 0.06% 499
2025
Q4 		$7.51M Sell
126,351
-71,678
-36% -$3.9M 0.21% 133
2025
Q3 		$10.7M Buy
198,029
+68,469
+53% +$3.92M 0.31% 56
2025
Q2 		$7.12M Buy
129,560
+68,928
+114% +$4.06M 0.2% 186
2025
Q1 		$4.29M Sell
60,632
-84,364
-58% -$5.68M 0.15% 275
2024
Q4 		$9.53M Buy
144,996
+116,434
+408% +$7.8M 0.41% 16
2024
Q3 		$2.01M Buy
+28,562
New +$2.39M 0.09% 401
2024
Q2 		– Sell
-19,678
Closed -$1.72M – 858
2024
Q1 		$1.72M Buy
+19,678
New +$1.76M 0.09% 369
2023
Q3 		– Sell
-9,180
Closed -$796K – 822
2023
Q2 		$796K Sell
9,180
-3,429
-27% -$323K 0.07% 409
2023
Q1 		$1.23M Buy
+12,609
New +$1.31M 0.14% 246
2022
Q4 		– Sell
-3,026
Closed -$257K – 512
2022
Q3 		$257K Sell
3,026
-1,560
-34% -$139K 0.02% 411
2022
Q2 		$380K Sell
4,586
-12,115
-73% -$965K 0.03% 433
2022
Q1 		$1.29M Buy
+16,701
New +$1.4M 0.1% 287

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Edgestream Partners's BMRN Position: Q2 2026 in Review

Edgestream Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 196% in Q2 2026, buying an estimated $3.66M and bringing the position to 100,897 shares worth $5.77M. The position accounts for 0.17% of the portfolio, ranked #202.

Edgestream Partners first reported a position in BMRN in Q1 2022 and has held it in 14 quarters since. The position peaked at $10.7M in Q3 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Edgestream Partners held 100,897 shares of BioMarin Pharmaceuticals worth $5.77M as of Q2 2026.
  • Edgestream Partners bought 66,842 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.66M.
  • BioMarin Pharmaceuticals made up 0.17% of Edgestream Partners's portfolio in Q2 2026, its #202 holding.
  • Edgestream Partners first reported a position in BioMarin Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Edgestream Partners's BioMarin Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.